Addicted to death: Invasive cancer and the immune response to unscheduled cell death

Journal of Immunotherapy

Volumn 28, Issue 1, 2005, Pages 1-9

  Zeh III, Herbert J ^a,b   Lotze, Michael T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Apoptosis; Chronic tumor lysis syndrome; Heat shock proteins; HMGB1; Necrosis; Purine metabolites; S100 molecules

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN S 100; URIC ACID;

ANGIOGENESIS; APOPTOSIS; BIOLOGICAL THERAPY; CANCER INVASION; CELL DEATH; CELLULAR IMMUNITY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MICROENVIRONMENT; NECROSIS; PRIORITY JOURNAL; PURINE METABOLISM; REVIEW; TUMOR GROWTH; TUMOR LYSIS SYNDROME;

EID: 11344282264     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-200501000-00001     Document Type: Review

References (161)

1. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004;101:4966-4971.
2. Weinberg RA. Inadvertent cancer research. Cancer Biol Ther. 2004;3:238-239.
3. Ohno S, Suzuki N, Ohno Y, et al. Tumor-associated macrophages: foe or accomplice of tumors? Anticancer Res. 2003;23:4395-4409.
4. Shekhar MP, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003;5:130-135.
5. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
6. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med. 2002;347:1593-1603.
7. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene. 2004;23:2746-2756.
8. Stergiou L, Hengartner MO. Death and more: DNA damage response pathways in the nematode C. elegans. Cell Death Differ. 2004;11:21-28.
9. Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359-1368.
10. Albert ML, Kim JI, Birge RB. alphavbeta5 integrin recruits the CrkII-Dock180-rac1 complex for phagocytosis of apoptotic cells. Nat Cell Biol. 2000;2:899-905.
11. Clayton AR, Prue RL, Harper L, et al. Dendritic cell uptake of human apoptotic and necrotic neutrophils inhibits CD40, CD80, and CD86 expression and reduces allogeneic T cell responses: relevance to systemic vasculitis. Arthritis Rheum. 2003;48:2362-2374.
12. Grolleau A, Misek DE, Kuick R, et al. Inducible expression of macrophage receptor Marco by dendritic cells following phagocytic uptake of dead cells uncovered by oligonucleotide arrays. J Immunol. 2003;171:2879-2888.
13. Morelli AE, Larregina AT, Shufesky WJ, et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood. 2003;101:611-620.
14. Steinman RM, Turley S, Mellman I, et al. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med. 2000;191:411-416.
15. Heath WR, Carbone FR. Immunology: dangerous liaisons. Nature. 2003;425:460-461.
16. Jerome KR, Corey L. The danger within. N Engl J Med. 2004;350:411-412.
17. Pulendran B. Immune activation: death, danger and dendritic cells. Curr Biol. 2004;14:R30-R32.
18. Fiuza C, Bustin M, Talwar S, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101:2652-2660.
19. Lotze MT, DeMarco RA. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr Opin Investig Drugs. 2003;4:1405-1409.
20. Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004;164:441-449.
21. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191-195.
22. Agnello D, Wang H, Yang H, et al. HMGB-1, a DNA-binding protein with cyiokine activity, induces brain TNF and IL-6 production, and mediates anorexia and taste aversion. Cytokine. 2002;18:231-236.
23. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-521.
24. Dai J, Liu B, Caudill MM, et al. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun. 2003;3:1.
25. Li Z, Dai J, Zheng H, Liu B, Caudill M. An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune response. Front Biosci. 2002;7:d731-d751.
26. Noessner E, Gastpar R, Milani V, et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol. 2002;169:5424-5432.
27. D'Ambrosi N, Murra B, Vacca F, Volonte C. Pathways of survival induced by NGF and extracellular ATP after growth factor deprivation. Prog Brain Res. 2004;146:93-100.
28. Schmidt-Hansen B, Omas D, Grigorian M, et al. Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene. 2004;23:5487-5495.
29. Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5:825-830.
30. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med. 2003;254:375-385.
31. Andersson UG, Tracey KJ. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J Intern Med. 2004;255:318-319.
32. Palumbo R, Sampaolesi M, De Marchis F, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol. 2004;164:441-449.
33. Rouhiainen A, Kuja-Panula J, Wilkman E, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood. 2004;104:1174-1182.
34. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004;173:307-313.
35. Andersson U, Wang H, Palmblad K, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565-570.
36. Andersson U, Erlandsson-Harris H, Yang H, et al. HMGB1 as a DNA-binding cytokine. J Leukoc Biol. 2002;72:1084-1091.
37. Bustin M. At the crossroads of necrosis and apoptosis: signaling to multiple cellular targets by HMGB1. Sci STKE. 2002;151:PE39.
38. Czura CJ, Yang H, Tracey KJ. High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor. J Infect Dis. 2003;187(Suppl 2):S391-S396.
39. Czura CJ, Yang H, Amelia CA, Tracey KJ. HMGB1 in the immunology of sepsis (not septic shock) and arthritis. Adv Immunol. 2004;84:181-200.
40. Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004;64:5564-5569.
41. Emberley ED, Murphy LC, Watson PH. S100A7 and the progression of breast cancer. Breast Cancer Res. 2004;6:153-159.
42. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol. 2004;82:508-515.
43. Lin J, Yang Q, Yan Z, et al. Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem. 2004;279:34071-34077.
44. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 2004;322:1111-1122.
45. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22:5551-5560.
46. Gardella S, Andrei C, Ferrera D, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 2002;3:995-1001.
47. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol. 2003;201:63-74.
48. Missiaglia E, Blaveri E, Terris B, et al. Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer. 2004;112:100-112.
49. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol. 1999;17:1891-1896.
50. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem. 2004;37:512-518.
51. Molina R, Navarro J, Filella X, et al. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 2002;23:39-44.
52. Rosty C, Ueki T, Argani P, et al. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol. 2002;160:45-50.
53. Wollina U, Karte K, Hipler UC, et al. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay. J Cancer Res Clin Oncol. 2000;126:107-110.
54. Eue I, Konig S, Pior J, et al. S100A8, S100A9 and the S100A8/A9 heterodimer complex specifically bind to human endothelial cells: identification and characterization of ligands for the myeloid-related proteins S100A9 and S100A8/A9 on human dermal microvascular endothelial cell line-1 cells. Int Immunol. 2002;14:287-297.
55. Passey RJ, Williams E, Lichanska AM, et al. A null mutation in the inflammation-associated S100 protein S100A8 causes early resorption of the mouse embryo. J Immunol. 1999;163:2209-2216.
56. Ryckman C, Vandal K, Rouleau P, et al. Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol. 2003;170:3233-3242.
57. Ryckman C, McColl SR, Vandal K, et al. Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum. 2003;48:2310-2320.
58. Andersen K, Smith-Sorensen B, Pedersen KB, et al. Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. Br J Cancer. 2003;88:1995-2001.
59. Grigorian M, Andresen S, Tulchinsky E, et al. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem. 2001;276:22699-22708.
60. Komatsu K, Andoh A, Ishiguro S, et al. Increased expression of S100A6 (Calcyclin), a calcium-binding protein of the S100 family, in human colorectal adenocarcinomas. Clin Cancer Res. 2000;6:172-177.
61. Komatsu K, Kobune-Fujiwara Y, Andoh A, et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer. 2000;83:769-774.
62. Komatsu K, Murata K, Kameyama M, et al. Expression of S100A6 and S100A4 in matched samples of human colorectal mucosa, primary colorectal adenocarcinomas and liver metastases. Oncology. 2002;63:192-200.
63. Mathisen B, Lindstad RI, Hansen J, et al. S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis. 2003;20:701-711.
64. Schmidt-Hansen B, Klingelhofer J, Grum-Schwensen B, et al. Functional significance of metastasis-inducing S100A4(Mts1) in tumor-stroma interplay. J Biol Chem. 2004;279:24498-24504.
65. la Sala A, Ferrari D, Di Virgilio F, et al. Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol. 2003;73:339-343.
66. Ferrari D, Chiozzi P, Falzoni S, et al. Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med. 1997;185:579-582.
67. Dutta AK, Sabirov RZ, Uramoto H, et al. Role of ATP-conductive anion channel in ATP release from neonatal rat cardiomyocytes in ischemic or hypoxic conditions. J Physiol. 2004;559:799-812.
68. Oury C, Sticker E, Cornelissen H, et al. ATP augments von Willebrand factor-dependent shear-induced platelet aggregation through Ca2+-calmodulin and myosin light chain kinase activation. J Biol Chem. 2004;279:26266-26273.
69. Rich PB, Douillet CD, Mahler SA, et al. Adenosine triphosphate is released during injurious mechanical ventilation and contributes to lung edema. J Trauma. 2003;55:290-297.
70. Srinivas SP, Mutharasan R, Fleiszig S. Shear-induced ATP release by cultured rabbit corneal epithelial cells. Adv Exp Med Biol. 2002;506:677-685.
71. Pastor-Anglada M, Casado FJ, Valdes R, et al. Complex regulation of nucleoside transporter expression in epithelial and immune system cells. Mol Membr Biol. 2001;18:81-85.
72. Idzko M, Dichmann S, Ferrari D, et al. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood. 2002;100:925-932.
73. Schnurr M, Toy T, Stoitzner P, et al. ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood. 2003;102:613-620.
74. la Sala A, Sebastiani S, Ferrari D, et al. Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. Blood. 2002;99:1715-1722.
75. la Sala A, Ferrari D, Corinti S, et al. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol. 2001;166:1611-1617.
76. Hasko G, Kuhel DG, Salzman AL, et al. ATP suppression of interleukin-12 and tumour necrosis factor-alpha release from macrophages. Br J Pharmacol. 2000;129:909-914.
77. Schnurr M, Toy T, Shin A, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 2004;103:1391-1397.
78. Bai L, Koopmann J, Fiola C, et al. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol. 2002;21:685-694.
79. Bausinger H, Lipsker D, Ziylan U, et al. Endotoxin-free heat-shock protein 70 fails to induce APC activation. Eur J Immunol. 2002;32:3708-3713.
80. Lipsker D, Ziylan U, Spehner D, et al. Heat shock proteins 70 and 60 share common receptors which are expressed on human monocyte-derived but not epidermal dendritic cells. Eur J Immunol. 2002;32:322-332.
81. Bethke K, Staib F, Distler M, et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol. 2002;169:6141-6148.
82. Delneste Y. Scavenger receptors and heat-shock protein-mediated antigen cross-presentation. Biochem Soc Trans. 2004;32:633-635.
83. Flohe SB, Bruggemann J, Lendemans S, et al. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol. 2003;170:2340-2348.
84. Kammerer R, Stober D, Riedl P, et al. Noncovalent association with stress protein facilitates cross-priming of CD8+ T cells to tumor cell antigens by dendritic cells. J Immunol. 2002;168:108-117.
85. Tsan MF, Gao B. Cytokine function of heat shock proteins. Am J Physiol Cell Physiol. 2004;286:C739-C744.
86. Li Z, Srivastava PK. A critical contemplation on the role of heat shock proteins in transfer of antigenic peptides during antigen presentation. Behring Inst Mitt. 1994;94:37-47.
87. Maki RG, Old LJ, Srivastava PK. Human homologue of murine tumor rejection antigen gp96: 5′-regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci USA. 1990;87:5658-5662.
88. Maki RG, Eddy RL Jr, Byers M, et al. Mapping of the genes for human endoplasmic reticular heat shock protein gp96/grp94. Somat Cell Mol Genet. 1993;19:73-81.
89. Palladino MA, Shalaby MR, Kramer SM, et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987;138:4023-4032.
90. Berwin B, Hart JP, Pizzo SV, et al. Cutting edge: CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J Immunol. 2002;168:4282-4286.
91. Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med. 2000;191:423-434.
92. Somersan S, Larsson M, Fonteneau JF, et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol. 2001;167:4844-4852.
93. Berwin B, Reed RC, Nicchitta CV. Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96. J Biol Chem. 2001;276:21083-21088.
94. Binder RJ, Srivastava PK. Essential role of CD91 in re-presentation of gp96-chaperonedpeptides. Proc Natl Acad Sci USA. 2004;101:6128-6133.
95. Castelli C, Rivoltini L, Rini F, et al. Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. Cancer Immunol Immunother. 2004;53:227-233.
96. Doody AD, Kovalchin JT, Mihalyo MA, et al. Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function. J Immunol. 2004;172:6087-6092.
97. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003;9:3235-3245.
98. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol. 2004;6:507-514.
99. Eustace BK, Jay DG. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle. 2004;3.
100. Grenert JP, Johnson BD, Toft DO. The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. J Biol Chem. 1999;274:17525-17533.
101. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets. 2003;3:349-358.
102. Baumann MA, Frick JC, Holoye PY. The tumor lysis syndrome. JAMA. 1983;250:615.
103. Boles JM, Dutel JL, Briere J, et al. Acute renal failure caused by extreme hyperphosphatemia after chemotherapy of an acute lymphoblastic leukemia. Cancer. 1984;53:2425-2429.
104. Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma. Am J Med. 1980;68:486-491.
105. Fer MF, Bottino GC, Sherwin SA, et al. Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Am J Med. 1984;77:953-956.
106. Vogelzang NJ, Nelimark RA, Nath KA. Tumor lysis syndrome after induction chemotherapy of small-cell bronchogenic carcinoma. JAMA. 1983;249:513-514.
107. Davidson MB, Thakkar S, Hix JK, et al. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med. 2004;116:546-554.
108. Hsu HH, Chan YL, Huang CC. Acute spontaneous tumor lysis presenting with hyperuricemic acute renal failure: clinical features and therapeutic approach. J Nephrol. 2004;17:50-56.
109. Sorscher SM. Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer. Cancer Chemother Pharmacol. 2004;54:191-192.
110. Tanvetyanon T, Choudhury AM. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004;171:1627.
111. Dizdar O, Yurekli BS, Purnak T, et al. Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia. Ann Pharmacother. 2004;38:1319-1320.
112. Yamazaki H, Kanada M, Horiki M, et al. Acute tumor lysis syndrome caused by palliative radiotherapy in patients with diffuse large B-cell lymphoma. Radiat Med. 2004;22:52-55.
113. Barry BD, Kell MR, Redmond HP. Tumor lysis syndrome following endoscopic radiofrequency interstitial thermal ablation of colorectal liver metastases. Surg Endosc. 2002;16:1109.
114. Kurt M, Eren OO, Engin H, et al. Tumor lysis syndrome following a single dose of capecitabine. Ann Pharmacother. 2004;38:902.
115. Cany L, Fitoussi O, Boiron JM, et al. Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma. J Clin Oncol. 2002;20:2212.
116. Fuente N, Mane JM, Barcelo R, et al. Tumor lysis syndrome in a multiple myeloma treated with thalidomide. Ann Oncol. 2004;15:537.
117. Trobaugh-Lotrario AD, Liang X, Janik JS, et al. Difficult diagnostic and therapeutic cases: Case 2. Thymoma and tumor lysis syndrome in an adolescent. J Clin Oncol. 2004;22:955-957.
118. Busam KJ, Wolchok J, Jungbluth AA, et al. Diffuse melanosis after chemotherapy-induced tumor lysis syndrome in a patient with metastatic melanoma. J Cutan Pathol. 2004;31:274-280.
119. Hsu HH, Huang CC. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. Int J Hematol. 2004;79:48-51.
120. Beriwal S, Singh S, Garcia-Young JA. Tumor lysis syndrome in extensive-stage small-cell lung cancer. Am J Clin Oncol. 2002;25:474-475.
121. Lovelace K, vanGessel Y, Asher LV, et al. Spontaneous acute tumor lysis syndrome in a DBA/1J mouse: a case report and review. Toxicol Pathol. 2003;31:486-490.
122. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother. 2003;37:1047-1054.
123. Hummel M, Buchheidt D, Reiter S, et al. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia. 2003;17:2542-2544.
124. Lee AC, Li CH, So KT, et al. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother. 2003;37:1614-1617.
125. Albert ML. Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol. 2004;4:223-231.
126. Lucas M, Stuart LM, Savill J, et al. Apoptotic cells and innate immune stimuli combine to regulate macrophage cytokine secretion. J Immunol. 2003;171:2610-2615.
127. Reddy SM, Hsiao KH, Abernethy VE, et al. Phagocytosis of apoptotic cells by macrophages induces novel signaling events leading to cytokine-independent survival and inhibition of proliferation: activation of Akt and inhibition of extracellular signal-regulated kinases 1 and 2. J Immunol. 2002;169:702-713.
128. Stuart LM, Lucas M, Simpson C, et al. Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol. 2002;168:1627-1635.
129. Clancy RM, Buyon JP. Clearance of apoptotic cells: TGF-beta in the balance between inflammation and fibrosis. J Leukoc Biol. 2003;74:959-960.
130. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest. 2002;109:41-50.
131. Fadok VA, Bratton DL, Guthrie L, et al. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol. 2001;166:6847-6854.
132. Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect. 2003;5:515-526.
133. Flohr AM, Rogalla P, Meiboom M, et al. Variation of HMGB1 expression in breast cancer. Anticancer Res. 2001;21:3881-3885.
134. Flohr AM, Rogalla P, Bonk U, et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol. 2003;18:999-1004.
135. Meyer B, Murua EH, Hauke S, et al. Expression pattern of the HMGB1 gene in sarcomas of the dog. Anticancer Res. 2004;24:707-710.
136. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med. 2004;255:332-343.
137. Nestl A, Von Stein OD, Zatloukal K, et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res. 2001;61:1569-1577.
138. Kuniyasu H, Chihara Y, Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol Rep. 2003;10:445-448.
139. Taguchi A, Blood DC, del Toro G, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000;405:354-360.
140. Re RN. The intracrine hypothesis and intracellular peptide hormone action. Bioessays. 2003;25:401-409.
141. Werman A, Werman-Venkert R, White R, et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA. 2004;101:2434-2439.
142. Nelson DA, Tan TT, Rabson AB, et al. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev. 2004;18:2095-2107.
143. Ramp U, Krieg T, Caliskan E, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol. 2004;35:1022-1028.
144. Giatromanolaki A, Koukourakis MI, Sowter HM, et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res. 2004;10:5566-5571.
145. Sowter HM, Ferguson M, Pym C, et al. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. J Pathol. 2003;201:573-580.
146. Formigli L, Papucci L, Tani A, et al. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell Physiol. 2000;182:41-49.
147. Papucci L, Formigli L, Schiavone N, et al. Apoptosis shifts to necrosis via intermediate types of cell death by a mechanism depending on c-myc and bcl-2 expression. Cell Tissue Res. 2004;316:197-209.
148. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol. 1993;11:1929-1935.
149. Kato T, Kameoka S, Kirmira T, et al. p53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Res. 2002;22:1105-1112.
150. Kato T, Kameoka S, Kimura T, et al. The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer. 2003;88:1900-1908.
151. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395-2400.
152. Cheville JC, Blute ML, Zincke H, et al. Stage pT1 conventional (clear cell) renal cell carcinoma: pathological features associated with cancer specific survival. J Urol. 2001;166:453-456.
153. Hunter GJ, Willson SA, Chapman M. Necrotic carcinoma of the colon. Clin Radiol. 1983;34:297-299.
154. Rubio CA. Colorectal carcinomas. Possible mechanisms of local tumor progression. Anticancer Res. 2003;23:347-350.
155. Gustafson P, Akerman M, Alvegard TA, et al. Prognostic information in soft tissue sarcoma using tumour size, vascular invasion and microscopic tumour necrosis-the SIN-system. Eur J Cancer. 2003;39:1568-1576.
156. Hasegawa T, Yamamoto S, Yokoyama R, et al. Prognostic significance of grading and staging systems using MIB-1 score in adult patients with soft tissue sarcoma of the extremities and trunk. Cancer. 2002;95:843-851.
157. Miyajima K, Oda Y, Oshiro Y, et al. Clinicopathological prognostic factors in soft tissue leiomyosarcoma: a multivariate analysis. Histopathology. 2002;40:353-359.
158. Cole DJ, Taubenberger JK, Pockaj BA, et al. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother. 1994;38:299-303.
159. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-251.
160. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25:243-251.
161. Rosenberg SA, Yang JC, Robbins PF, et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003;26:385-393.